



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/22	A2	(11) International Publication Number: WO 96/36318 (43) International Publication Date: 21 November 1996 (21.11.96)
(21) International Application Number: PCT/SI96/00012 (22) International Filing Date: 17 May 1996 (17.05.96) (30) Priority Data: P-9500173 19 May 1995 (19.05.95) SI (71) Applicant (for all designated States except US): LEK, TOVARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOVI, D.D. [SI/SI]; Verovškova 57, 1526 Ljubljana (SI). (72) Inventors; and (75) Inventors/Applicants (for US only): KERČ, Janez [SI/SI]; Trebinjska 7, 1000 Ljubljana (SI). REBIČ, Ljubomira, Barbara [SI/SI]; Dergomaška 50, 1000 Ljubljana (SI). KOFLER, Bojan [SI/SI]; Podlubnik 301, 4220 Škofja Loka (SI). (74) Agent: PATENTNA PISARNA D.O.O.; Čopova 14, P.O. Box 322, 1000 Ljubljana (SI).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: THREE-PHASE PHARMACEUTICAL FORM WITH CONSTANT AND CONTROLLED RELEASE OF AMORPHOUS ACTIVE INGREDIENT FOR SINGLE DAILY APPLICATION		
(57) Abstract Described is a novel three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient stabilized with polymers for a single daily peroral application, which is especially suitable for active ingredients existing in amorphous form or in one or more polymorphous forms, which exhibit poor solubility in crystal form depending on the polymorphous form, particle size and the specific surface area of the active ingredient. The active ingredient can be used in its amorphous or any polymorphous form, which in the process of the preparation of the three-phase pharmaceutical form according to the invention is converted into the amorphous form. The three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient for a single daily peroral application contains a core consisting of a first and a second phase and a coating representing the third phase. In the first phase the three-phase pharmaceutical form contains an amorphous active ingredient, the water-soluble polymer polyvinylpyrrolidone and a cellulose ether as carriers of the amorphous active ingredient and simultaneously as inhibitors of its crystallization, a surfactant that improves the solubility of the active ingredient and promotes the absorption of the amorphous active ingredient from gastrointestinal tract, in the second phase it contains a cellulose ether and a mixture of mono-, di- and triglycerides as sustained release agents and the third phase is represented by a poorly soluble or gastro-resistant film coating, which in the first few hours after the application controls the release of the active ingredient and can consist of an ester of hydroxypropylmethylcellulose with phthalic anhydride or of a copolymerizate based on methacrylic acid and ethyl acrylate. Described is also a process for the preparation of this pharmaceutical form.		

Exhibit 1022

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**Three-phase Pharmaceutical Form with Constant and Controlled Release of
Amorphous Active Ingredient for Single Daily Application**

Technical Field of the Invention

IPC A 61K 9/22

The invention belongs to the field of pharmaceutical industry and relates to a novel medicinal preparation with prolonged action for peroral application (sustained release tablets) based on a combination of an amorphous active ingredient, water-soluble polymer polyvinylpyrrolidone, cellulose ethers and a mixture of mono-, di- and triglycerides, an ester of hydroxypropylmethylcellulose with phthalic anhydride or a copolymer based on methacrylic acid and ethyl acrylate.

Particularly, the invention relates to a novel three-phase pharmaceutical form with a constant and controlled release of an amorphous active ingredient stabilized with polymers for a single daily peroral application such as tablets and capsules. A three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient for a single daily peroral application is especially suitable for active ingredients existing in amorphous form or in one or more polymorphous forms, which exhibit poor solubility in crystal form depending on the polymorphous form, particle size and specific surface area of the active ingredient. The active ingredient can be used in amorphous or any polymorphous form which is converted into the amorphous form during the manufacturing process of the three-phase pharmaceutical form of the invention. The three-phase pharmaceutical form with constant and controlled release of the amorphous active ingredient for a single daily peroral application contains a core consisting of a first and a second phase and a coating representing the third phase. The three-phase pharmaceutical form contains as the first phase an amorphous active ingredient, the water-soluble polymer polyvinylpyrrolidone and a cellulose ether as carriers of the amorphous active ingredient and simultaneously as inhibitors of crystallization of the amorphous active ingredient as well as a surfactant improving the solubility of the active ingredient and promoting the absorption of the amorphous active ingredient from the gastrointestinal tract; as the second phase it contains sustained-release agents such as cellulose ether and a mixture of mono-, di- and triglycerides, and the third phase is represented by a poorly soluble or gastro-resistant film coating, which in the first few hours after the application controls the release of the active ingredient and can consist of an ester of

hydroxypropylmethylcellulose with phthalic anhydride or of a copolymerizate based on methacrylic acid and ethyl acrylate.

Technical Problem

There exists a constant need to develop pharmaceutical forms in which solubility and dissolution rate of the active ingredient will be independent of its polymorphous form, crystallinity, particle size and specific surface area. Hitherto known pharmaceutical forms with prolonged release of the active ingredient containing a crystalline active ingredient in the pharmaceutical form have the essential disadvantage that, due to the presence of the crystalline active ingredient in several polymorphous modifications, the release rate of the active ingredient depends on the polymorphous modification, the crystal size and thus on the specific surface area of the active ingredient. The dissolution rate of a crystalline substance is not constant and it changes depending on various shapes and size distribution of the crystals of the active ingredient.

Prior Art

The use of cellulose ethers of various viscosities and molecular weights in the function of controlling the release rate has been known for a long time. In US patent 4,259,314 there is described a method for the preparation of a dry pharmaceutical preparation with controlled and sustained release, which is provided by a mixture of hydroxypropylmethylcellulose and hydroxypropylcellulose together with a hygroscopic active ingredient.

N.A. Shaikh, S.E. Abidi and L.H. Block (Drug Development and Industrial Pharmacy, 13 (8), 1345-1369 (1987)) studied the influence of the concentration of ethylcellulose in a pharmaceutical preparation on the release rate of the active ingredient (e.g. acetaminophen, theophylline). It was found that the higher is the viscosity of ethylcellulose the lower is the release rate of the active ingredient from a solid dispersion.

In US patent 4,389,393 there is described a carrier basis for active ingredients consisting of one or more hydroxypropylmethylcelluloses with various contents of methoxy or hydroxypropoxy groups and various average molecular weights, which combination gives a pharmaceutical preparation with sustained release.

In US patent 4,792,452 there is described a pharmaceutical form with a controlled release of the active ingredient (selected from the group of calcium antagonists) independently of the pH-value of the environment, which contains up to 45 wt.% of a polymer dependent of the pH value, which is an alginic acid salt e.g. sodium alginate, and a gelatinizing agent independent of the pH-value such as hydroxypropylmethylcellulose.

In WO 87/00044 there is described the use of bimodal hydroxypropylmethylcellulose in a carrier basis which together with the active ingredient gives a bimodal profile of the release of the active ingredient.

In WO 91/17743 a pharmaceutical preparation for a slow release of granules containing low and high viscous ethylcellulose is described.

In US patent 5,009,895 there is described a carrier basis in combination with an active ingredient (e.g. ibuprofen or its salt) that is formed and compressed in a solid pharmaceutical form with a sustained release of the active ingredient. The carrier basis contains two hydroxypropylmethylcelluloses of different viscosities in such a ratio that the release rate of the active ingredient is of zero order. In the pharmaceutical form there is also present polyvinylpyrrolidone (Povidon USP) acting as a binding agent.

In EP-A-596 203 there is described a pharmaceutical form containing solid particles, which is prepared by mixing an active ingredient (e.g. nifedipine) with a water-soluble melt consisting of two sorts of polymers with different viscosities (polymer A with a viscosity from 1000 to 120000 mPa.s, polymer B with a viscosity from 1 to 500 mPa.s) as a carrier.

A dosage form containing cellulose ethers with various molecular weights is described also in US patent 4,871,548.

In US patent 5,015,479, there is described a pharmaceutical preparation for a single daily application in the form of an adsorbate containing amorphous dihydropyridine (such as felodipine, nicardipine, nifedipine) and polyvinylpyrrolidone with average molecular weight above 55000 g/mol, whose role is to change the dissolution rate of dihydropyridine from cross-linked polyvinylpyrrolidone and to prevent the crystallization of dihydropyridine. Dihydropyridine and polyvinylpyrrolidone are adsorbed on cross-linked polyvinylpyrrolidone and mixed with a polymer which gelatinates in

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.